Action RPHM RENEO PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Reneo Pharmaceuticals, Inc.

Actions

RPHM

US75974E1038

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
1,52 USD 0,00 % Graphique intraday de Reneo Pharmaceuticals, Inc. +1,33 % -5,00 %
16/05 Un initié de Reneo Pharmaceuticals a acheté des actions pour une valeur de 639 578 $, selon un récent dépôt auprès de la SEC MT
13/05 Reneo Pharmaceuticals fusionne avec OnKure dans le cadre d'une transaction entièrement en actions -- Les actions de Reneo augmentent MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
PR
RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM
BU
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM
PR
Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure
PR
RPHM Alert: Monsey Firm of Wohl & Fruchter Investigating Proposed Merger of Reneo Pharmaceuticals With OnKure
AQ
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
BU
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
GL
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
GL
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
GL
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
GL
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
AQ
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
GL
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
AQ
Women in Stem with Ashley Hall
AQ
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
GL
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
AQ
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
GL
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
AQ
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RPHM
  4. Actualités Reneo Pharmaceuticals, Inc.
  5. Communiqués